期刊文献+

Development and Validation of a Carbohydrate Metabolism-Related Model for Predicting Prognosis and Immune Landscape in Hepatocellular Carcinoma Patients

下载PDF
导出
摘要 Objective The activities and products of carbohydrate metabolism are involved in key processes of cancer.However,its relationship with hepatocellular carcinoma(HCC)is unclear.Methods The cancer genome atlas(TCGA)-HCC and ICGC-LIRI-JP datasets were acquired via public databases.Differentially expressed genes(DEGs)between HCC and control samples in the TCGA-HCC dataset were identified and overlapped with 355 carbohydrate metabolism-related genes(CRGs)to obtain differentially expressed CRGs(DE-CRGs).Then,univariate Cox and least absolute shrinkage and selection operator(LASSO)analyses were applied to identify risk model genes,and HCC samples were divided into high/low-risk groups according to the median risk score.Next,gene set enrichment analysis(GSEA)was performed on the risk model genes.The sensitivity of the risk model to immunotherapy and chemotherapy was also explored.Results A total of 8 risk model genes,namely,G6PD,PFKFB4,ACAT1,ALDH2,ACYP1,OGDHL,ACADS,and TKTL1,were identified.Moreover,the risk score,cancer status,age,and pathologic T stage were strongly associated with the prognosis of HCC patients.Both the stromal score and immune score had significant negative/positive correlations with the risk score,reflecting the important role of the risk model in immunotherapy sensitivity.Furthermore,the stromal and immune scores had significant negative/positive correlations with risk scores,reflecting the important role of the risk model in immunotherapy sensitivity.Eventually,we found that high-/low-risk patients were more sensitive to 102 drugs,suggesting that the risk model exhibited sensitivity to chemotherapy drugs.The results of the experiments in HCC tissue samples validated the expression of the risk model genes.Conclusion Through bioinformatic analysis,we constructed a carbohydrate metabolism-related risk model for HCC,contributing to the prognosis prediction and treatment of HCC patients.
出处 《Current Medical Science》 SCIE CAS 2024年第4期771-788,共18页 当代医学科学(英文)
基金 supported by grants from the National Natural Science Foundation for Young Scientists of China(No.82103339) the National Natural Science Foundation for Regional Fund(No.82360507) the Natural Science Fund for Youths of Jiangxi Province(No.20224BAB216067 and No.20202BABL216002).
  • 相关文献

参考文献4

二级参考文献47

  • 1Meetings[J].World Journal of Gastroenterology,2010,16(1). 被引量:25
  • 2Amilcare Parisi,Jacopo Desiderio,Stefano Trastulli,Elisa Castellani,Rosario Pasquale,Roberto Cirocchi,Carlo Boselli,Giuseppe Noya.Liver resection versus radiofrequency ablation in the treatment of cirrhotic patients with hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2013,12(3):270-277. 被引量:8
  • 3K.‐C. Lim,P. K.‐H. Chow,J. C. Allen,F. J. Siddiqui,E. S.‐Y. Chan,S.‐B. Tan.Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria[J]. Br J Surg . 2012 (12) 被引量:1
  • 4Ahsan Rao,Ghaus Rao,Irfan Ahmed.Laparoscopic or open liver resection? Let systematic review decide it[J]. The American Journal of Surgery . 2012 (2) 被引量:1
  • 5Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J]. The Lancet . 2012 (9822) 被引量:1
  • 6Marta Burrel,María Reig,Alejandro Forner,Marta Barrufet,Carlos Rodríguez de Lope,Silvia Tremosini,Carmen Ayuso,Josep M Llovet,María Isabel Real,Jordi Bruix.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design[J]. Journal of Hepatology . 2012 (6) 被引量:1
  • 7R. Lencioni,M. Kudo,S.‐L. Ye,J.‐P. Bronowicki,X.‐P. Chen,L. Dagher,J. Furuse,J. F. Geschwind,L. L. de Guevara,C. Papandreou,A. J. Sanyal,T. Takayama,S. K. Yoon,K. Nakajima,F. Cihon,S. Heldner,J. A. Marrero.First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study[J]. International Journal of Clinical Practice . 2012 (7) 被引量:1
  • 8European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. Journal of Hepatology . 2012 (4) 被引量:1
  • 9C.-Y. Yu,H.-Y. Ou,T.-L. Huang,T.-Y. Chen,L.L.-C. Tsang,C.-L. Chen,Y.-F. Cheng.Hepatocellular Carcinoma Downstaging in Liver Transplantation[J]. Transplantation Proceedings . 2012 (2) 被引量:1
  • 10Bingru Xie,David Wang,Stuart Spechler.Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review[J]. Digestive Diseases and Sciences . 2012 (5) 被引量:1

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部